FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885682912> ?p ?o ?g. }

• W2885682912 endingPage "2245" @default.
• W2885682912 startingPage "2231" @default.
• W2885682912 abstract "Background: Patients undergoing percutaneous coronary intervention react differently to antiplatelet drugs. Those with low responsiveness to clopidogrel have a higher risk of cardiac ischemic events. The goal of this study is to conduct a head-to-head comparison of the safety and effectiveness of intensified antiplatelet therapies (either double-dose clopidogrel [DOUBLE] or adjunctive cilostazol [TRIPLE]) and conventional strategy (STANDARD) in patients after percutaneous coronary intervention. Methods: In this single-center, randomized, controlled trial, we used thromboelastography, a platelet function test, to select 1078 patients undergoing percutaneous coronary intervention at high thrombotic risk and compared the intensified antiplatelet therapies with standard antiplatelet therapy. The primary outcome was the incidence of major adverse cardiac and cerebrovascular events at 18 months after percutaneous coronary intervention, defined as a composite of all-cause death, myocardial infarction, target vessel revascularization, or stroke. Bleeding Academic Research Consortium defined bleeding complications (types 1, 2, 3, or 5) were the safety end points. Results: The primary end point occurred in 52 patients (14.4%) in the STANDARD group, 38 patients (10.6%) in the DOUBLE group, and 30 patients (8.5%) in the TRIPLE group (hazard ratio, 0.720; 95% confidence interval, 0.474–1.094, DOUBLE versus STANDARD; hazard ratio, 0.550; 95% confidence interval, 0.349–0.866, TRIPLE versus STANDARD). No significant difference in the rates of major bleeding (Bleeding Academic Research Consortium grade≥3) was found in the DOUBLE group (3.34% versus 1.93% in STANDARD, P =0.133) and the TRIPLE group (2.53% versus 1.93% in STANDARD, P =0.240). The rate of Bleeding Academic Research Consortium–defined minor bleeding increased in the DOUBLE group (27.4% versus 20.3% in STANDARD, P =0.031), but not in the TRIPLE group (23.6% versus 20.3% in STANDARD, P =0.146). Conclusions: In patients with low responsiveness to clopidogrel, as measured by thromboelastography, the intensified antiplatelet strategies with adjunctive use of cilostazol significantly improved the clinical outcomes without increasing the risk of major bleeding. Decreased trend of negative outcomes could be observed in patients with double dosage of clopidogrel, but the difference was not significant. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01779401." @default.
• W2885682912 created "2018-08-22" @default.
• W2885682912 creator A5003019918 @default.
• W2885682912 creator A5009171180 @default.
• W2885682912 creator A5009307990 @default.
• W2885682912 creator A5009430736 @default.
• W2885682912 creator A5010158256 @default.
• W2885682912 creator A5014105170 @default.
• W2885682912 creator A5017369508 @default.
• W2885682912 creator A5025289398 @default.
• W2885682912 creator A5026624461 @default.
• W2885682912 creator A5028828620 @default.
• W2885682912 creator A5035643880 @default.
• W2885682912 creator A5037178203 @default.
• W2885682912 creator A5038165898 @default.
• W2885682912 creator A5042484728 @default.
• W2885682912 creator A5043157513 @default.
• W2885682912 creator A5045349004 @default.
• W2885682912 creator A5047886846 @default.
• W2885682912 creator A5048379858 @default.
• W2885682912 creator A5051645715 @default.
• W2885682912 creator A5066911325 @default.
• W2885682912 creator A5073499085 @default.
• W2885682912 creator A5075782732 @default.
• W2885682912 creator A5076403164 @default.
• W2885682912 creator A5090210069 @default.
• W2885682912 creator A5091633599 @default.
• W2885682912 date "2018-05-22" @default.
• W2885682912 modified "2023-10-02" @default.
• W2885682912 title "Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity" @default.
• W2885682912 cites W1726466368 @default.
• W2885682912 cites W1891516986 @default.
• W2885682912 cites W1965044495 @default.
• W2885682912 cites W1983980229 @default.
• W2885682912 cites W1990018236 @default.
• W2885682912 cites W2003449402 @default.
• W2885682912 cites W2012343501 @default.
• W2885682912 cites W2021241943 @default.
• W2885682912 cites W2041379086 @default.
• W2885682912 cites W2048708470 @default.
• W2885682912 cites W2049913259 @default.
• W2885682912 cites W2059748659 @default.
• W2885682912 cites W2066618227 @default.
• W2885682912 cites W2071476382 @default.
• W2885682912 cites W207590421 @default.
• W2885682912 cites W2076921060 @default.
• W2885682912 cites W2078009181 @default.
• W2885682912 cites W2080880286 @default.
• W2885682912 cites W2084673482 @default.
• W2885682912 cites W2087150869 @default.
• W2885682912 cites W2088939881 @default.
• W2885682912 cites W2094667843 @default.
• W2885682912 cites W2095800857 @default.
• W2885682912 cites W2100771558 @default.
• W2885682912 cites W2107797912 @default.
• W2885682912 cites W2110108344 @default.
• W2885682912 cites W2117162232 @default.
• W2885682912 cites W2122779695 @default.
• W2885682912 cites W2135583792 @default.
• W2885682912 cites W2136050281 @default.
• W2885682912 cites W2140501627 @default.
• W2885682912 cites W2144206796 @default.
• W2885682912 cites W2145323902 @default.
• W2885682912 cites W2157833432 @default.
• W2885682912 cites W2159858918 @default.
• W2885682912 cites W2160328769 @default.
• W2885682912 cites W2161785946 @default.
• W2885682912 cites W2165349656 @default.
• W2885682912 cites W2418225445 @default.
• W2885682912 cites W2509918966 @default.
• W2885682912 cites W27443843 @default.
• W2885682912 cites W4236531408 @default.
• W2885682912 cites W4251532161 @default.
• W2885682912 cites W4376848313 @default.
• W2885682912 cites W9692900 @default.
• W2885682912 doi "https://doi.org/10.1161/circulationaha.117.030190" @default.
• W2885682912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29420189" @default.
• W2885682912 hasPublicationYear "2018" @default.
• W2885682912 type Work @default.
• W2885682912 sameAs 2885682912 @default.
• W2885682912 citedByCount "65" @default.
• W2885682912 countsByYear W28856829122018 @default.
• W2885682912 countsByYear W28856829122019 @default.
• W2885682912 countsByYear W28856829122020 @default.
• W2885682912 countsByYear W28856829122021 @default.
• W2885682912 countsByYear W28856829122022 @default.
• W2885682912 countsByYear W28856829122023 @default.
• W2885682912 crossrefType "journal-article" @default.
• W2885682912 hasAuthorship W2885682912A5003019918 @default.
• W2885682912 hasAuthorship W2885682912A5009171180 @default.
• W2885682912 hasAuthorship W2885682912A5009307990 @default.
• W2885682912 hasAuthorship W2885682912A5009430736 @default.
• W2885682912 hasAuthorship W2885682912A5010158256 @default.
• W2885682912 hasAuthorship W2885682912A5014105170 @default.
• W2885682912 hasAuthorship W2885682912A5017369508 @default.
• W2885682912 hasAuthorship W2885682912A5025289398 @default.
• W2885682912 hasAuthorship W2885682912A5026624461 @default.
• W2885682912 hasAuthorship W2885682912A5028828620 @default.

• next